Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Recent trends in modified mesenchymal stromal cells: engineering approaches and international regulatory landscape.

Created on 04 Aug 2026

Authors

S Gokul Krishna, Smitha Panigrahy, Uday Kumar Kolkundkar, Suresh Kannan

Published in

Molecular biology reports. Volume 53. Issue 1. Aug 04, 2026. Epub Aug 04, 2026.

Abstract

Mesenchymal stromal cells (MSCs) have demonstrated significant potential for various clinical applications; however, several challenges limit their therapeutic efficacy. These include donor variability, poor homing and survival after transplantation, reduced proliferative and differentiation potential during in vitro expansion, and the inflammatory microenvironment at the injury site. This review summarizes current strategies used to enhance the therapeutic potential of MSCs and discusses approaches to overcome these limitations. It also highlights key challenges and gaps in the existing literature that require further investigation. In addition, this structured review provides an overview of current research trends involving different MSC sources, disease models, preconditioning strategies, emerging gene modification approaches, and other methods to improve MSC function. Finally, regulatory considerations and the roles of global and regional regulatory authorities in ensuring the safety and quality of modified MSC-based therapies are briefly discussed.

PMID:
42550350
Bibliographic data and abstract were imported from PubMed on 04 Aug 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 59
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement